BioCentury | Aug 8, 2018
Distillery Therapeutics

Cancer

...Phase III testing to treat neurofibromatosis and in Phase II testing to treat various cancers. Dual Therapeutics LLC...
BioCentury | May 25, 2018
Company News

Astellas unveils new R&D strategy

Astellas Pharma Inc. (Tokyo:4503) President and CEO Kenji Yasukawa, who took the reins in April, unveiled his 2018 strategic plan for the company May 22, including a shift in R&D focus and restructuring of Japan...
BioCentury | Oct 3, 2017
Distillery Therapeutics

Other

...in Phase I testing for advanced solid tumors and preclinical testing for leukemia and depression. Dual Therapeutics LLC...
...doi:10.1126/scitranslmed.aaf7588 CONTACT: Huda Zoghbi, Baylor College of Medicine, Houston, Texas email: hzoghbi@bcm.edu Chris Lieu Baylor College of Medicine Dual Therapeutics LLC Lixte...
BioCentury | Jul 18, 2017
Distillery Therapeutics

Cancer

...increased tumor cell apoptosis compared with vehicle. Next steps include optimization of the PP2A activator. Dual Therapeutics LLC...
BioCentury | Jan 18, 2017
Translation in Brief

Keep a cool head

...before abandoning it in favor of more potent antitumor agents. Lixte Biotechnology Holdings Inc. (OTCQB:LIXT), Dual Therapeutics LLC...
BioCentury | Jan 25, 2016
Company News

Dual Therapeutics, Bristol-Myers deal

...compound approved in multiple indications, plus royalties. The partners declined to disclose additional financial terms. Dual Therapeutics LLC...
BioCentury | Jul 17, 2014
Targets & Mechanisms

New route for old cancer agents

Researchers at the University of Wisconsin-Madison and Cellectar Biosciences Inc. have exploited differences in lipid architecture between cancer and normal cells to create compounds that deliver radiolabels selectively to different types of malignant cells while...
BioCentury | Jun 23, 2014
Emerging Company Profile

Dual: Multi-pronged attack

...Companies and Institutions Mentioned Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan BioMotiv LLC , Cleveland, Ohio Dual Therapeutics LLC...
...& Johnson (NYSE:JNJ), New Brunswick, N.J. Oncotide Pharmaceuticals Inc. , Research Triangle Park, N.C. Sidebars Dual Therapeutics LLC...
BioCentury | May 12, 2014
Financial News

Dual Therapeutics completes venture financing

Dual Therapeutics LLC , Cleveland, Ohio Business: Cancer Date completed: 5/2/14 Type: Venture financing Raised: $250,000 Investor: Partnership Fund for New York City Note: The company received $250,000 of a milestone-based investment of up to $1...
BioCentury | Oct 14, 2013
Company News

BioMotiv, Dual Therapeutics, Icahn School of Medicine at Mount Sinai deal

...BioMotiv and the Icahn School of Medicine launched Dual Therapeutics to develop therapeutics to treat prostate and...
...funding from BioMotiv. The Icahn School of Medicine and BioMotiv declined to disclose details, and Dual Therapeutics...
...programs at a later stage (see BioCentury, July 2, 2012). BioMotiv LLC , Cleveland, Ohio Dual Therapeutics LLC...
Items per page:
1 - 10 of 12
BioCentury | Aug 8, 2018
Distillery Therapeutics

Cancer

...Phase III testing to treat neurofibromatosis and in Phase II testing to treat various cancers. Dual Therapeutics LLC...
BioCentury | May 25, 2018
Company News

Astellas unveils new R&D strategy

Astellas Pharma Inc. (Tokyo:4503) President and CEO Kenji Yasukawa, who took the reins in April, unveiled his 2018 strategic plan for the company May 22, including a shift in R&D focus and restructuring of Japan...
BioCentury | Oct 3, 2017
Distillery Therapeutics

Other

...in Phase I testing for advanced solid tumors and preclinical testing for leukemia and depression. Dual Therapeutics LLC...
...doi:10.1126/scitranslmed.aaf7588 CONTACT: Huda Zoghbi, Baylor College of Medicine, Houston, Texas email: hzoghbi@bcm.edu Chris Lieu Baylor College of Medicine Dual Therapeutics LLC Lixte...
BioCentury | Jul 18, 2017
Distillery Therapeutics

Cancer

...increased tumor cell apoptosis compared with vehicle. Next steps include optimization of the PP2A activator. Dual Therapeutics LLC...
BioCentury | Jan 18, 2017
Translation in Brief

Keep a cool head

...before abandoning it in favor of more potent antitumor agents. Lixte Biotechnology Holdings Inc. (OTCQB:LIXT), Dual Therapeutics LLC...
BioCentury | Jan 25, 2016
Company News

Dual Therapeutics, Bristol-Myers deal

...compound approved in multiple indications, plus royalties. The partners declined to disclose additional financial terms. Dual Therapeutics LLC...
BioCentury | Jul 17, 2014
Targets & Mechanisms

New route for old cancer agents

Researchers at the University of Wisconsin-Madison and Cellectar Biosciences Inc. have exploited differences in lipid architecture between cancer and normal cells to create compounds that deliver radiolabels selectively to different types of malignant cells while...
BioCentury | Jun 23, 2014
Emerging Company Profile

Dual: Multi-pronged attack

...Companies and Institutions Mentioned Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan BioMotiv LLC , Cleveland, Ohio Dual Therapeutics LLC...
...& Johnson (NYSE:JNJ), New Brunswick, N.J. Oncotide Pharmaceuticals Inc. , Research Triangle Park, N.C. Sidebars Dual Therapeutics LLC...
BioCentury | May 12, 2014
Financial News

Dual Therapeutics completes venture financing

Dual Therapeutics LLC , Cleveland, Ohio Business: Cancer Date completed: 5/2/14 Type: Venture financing Raised: $250,000 Investor: Partnership Fund for New York City Note: The company received $250,000 of a milestone-based investment of up to $1...
BioCentury | Oct 14, 2013
Company News

BioMotiv, Dual Therapeutics, Icahn School of Medicine at Mount Sinai deal

...BioMotiv and the Icahn School of Medicine launched Dual Therapeutics to develop therapeutics to treat prostate and...
...funding from BioMotiv. The Icahn School of Medicine and BioMotiv declined to disclose details, and Dual Therapeutics...
...programs at a later stage (see BioCentury, July 2, 2012). BioMotiv LLC , Cleveland, Ohio Dual Therapeutics LLC...
Items per page:
1 - 10 of 12